FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin

If approved, empagliflozin from Eli Lilly and Boehringer Ingelheim Pharmaceuticals would compete against AstraZeneca's Forxiga and Johnson & Johnson's Invokana.

Mar 5, 2014 at 12:57PM

Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership.

As rejections go, this one is pretty minor.

The FDA apparently observed deficiencies at the Boehringer Ingelheim manufacturing plant where empagliflozin is made and won't approve the drug until they're cleared up. The companies didn't say exactly what needed to be corrected, but it could be related to this lengthy FDA warning letter from last May.

Most importantly, the FDA isn't requiring the companies to run additional clinical trials to get empagliflozin approved like it did AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb's Forxiga. It took the companies two years to gather the data and get Foxiga approved earlier this year. AstraZeneca bought out Bristol-Myers Squibb's portion of their partnership, so it's now the full owner of Forxiga and the rest of their diabetes drugs.

Empagliflozin and Forxiga are inhibitors of sodium glucose co-transporter-2, or SGLT2, designed to inhibit the reabsorption of sugar by the kidney back into the bloodstream. The sugar is instead excreted in the patients' urine.

In addition to Forxiga, Eli Lilly will have to compete with Johnson & Johnson's (NYSE:JNJ) SGLT2 Invokana if empagliflozin is approved. In its fourth-quarter earnings report in January, Johnson & Johnson characterized Invokana sales as "strong" but didn't break out the actual sales  figures.

As a new class of drugs with a different mechanism of action, SGLT2 inhibitors are appealing because they can be used in conjunction with other diabetes medication. Last year, Merck (NYSE:MRK) and Pfizer (NYSE:PFE) teamed up to develop a combination product containing Merck's blockbuster Januvia and Pfizer's SGLT2 inhibitor ertugliflozin, an experimental drug in phase 3 trials.


Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and owns shares of the company. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers